Program 14 th Meeting of the IBCN October th, 2016, Bochum, Germany
|
|
|
- Rebecca Baldwin
- 5 years ago
- Views:
Transcription
1 THURSDAY, OCTOBER 27 TH, 2016 FRIDAY, OCTOBER 28 TH, :00 Welcome Dinner (Renaissance Hotel) Introduction Topic Speaker 07:30 08:00 Registration/Light breakfast 08:00 08:15 Welcome to IBCN Meeting Goebell/Kamat 08:15 08:20 Welcome to Bochum Brüning/Pesch Pipeline Topic Chair: Goebell 08:20 08:40 BMS: Immuno-oncologic approaches to TBA bladder 08:40 08:50 Discussion Pipeline Topic Chair: Kamat 08:50 09:10 Roche: Atezolizumab Clinical Legrand Development in NMIBC 09:10 09:20 Discussion Targeting novel Topic Chair: Kamat pathways 09:20 09:27 Oncofetal glycan, chemoresistance Daugaard (**Travel Award**) 09:27 09:34 HER2 and EGFR amplification and Eriksson expression 09:34 09:41 Chick embryo chorioallantoic membrane Skowron assay 09:41 09:48 Inhibition of protein kinase D as a Agarwal therapy for bladder 09:48 10:03 Discussion 10:03 10:10 Systemic therapy for urachal carcinoma Szarvas 10:10 10:17 Understanding of therapy resistance to Nawroth CDK4/6 inhibitors 10:17 10:24 Intratumoral anti-ctla4 administration Mangsbo 10:24 10:31 IMvigor 210 first line atezolizumab Necchi cisplatin ineligible 10:31 10:50 Discussion
2 FRIDAY, OCTOBER 28 TH, 2016 Break 10:50 11:05 Pipeline Topic Chair: Black 11:05 11:25 H3 Biomedicine: Evasion of immunosurveillance by genomic Korpal alterations of PPARg/RXRa 11:25 11:35 Discussion Virus Therapy Topic Chair: Nawroth 11:35 11:55 The multi-faceted mechanism of tumor Rommelaere suppression by oncolytic parvoviruses 11:55 12:10 Virotherapy plus PD-L1 inhibition Holm 12:10 12:25 AdIFN for BCG unresponsive NMIBC Dinney 12:25 12:45 Discussion Lunch Break 12:45 13:30 Pipeline Topic Chair: Kamat 13:30 13:50 TARIS Technology Update in Urothelial Cutie Carcinoma 13:50 14:00 Discussion Diagnosis & Risk Stratification Topic Chair: Schmitz- Dräger 14:00 14:15 Label-free imaging of bladder : Klaus Gerwer towards automated differential diagnostics 14:15 14:20 Discussion 14:20 14:27 Tele-cystoscopy Krupski 14:27 14:34 Diagnostic algorithms for asymptomatic Kuckuck microhematuria 14:34 14:41 UroFollow Biobank Johnen 14:41 14:50 Discussion 14:50 14:57 T1 substaging van Rhijn 14:57 15:04 Pathologic risk stratification of T1 Hansel bladder 15:04 15:10 Discussion 15:10 15:17 CTC pilot study Culp
3 15:17 15:24 ctdna in metastatic bladder carcinoma Todenhöfer 15:24 15:30 Discussion Industry meets Topic IBCN 15:30 Breakout groups Chair: Schmitz- Dräger Adjourn 16:30 Reconvene for Dinner 18:30 17:45 Bus transfer from Renaissance Hotel 18:30 Tour of Heinrichshütte (Museum) 20:00 Dinner at Heinrichs huette-hattingen/english 2230 Return bus transfer to Renaissance Hotel SATURDAY, OCTOBER 29 TH, 2016 Business Topic Meeting 08:00-09:00 IBCN Business Meeting with light breakfast (breakfast also available for those not attending the meeting) Speaker: Goebell/ Kamat Keynote Lecture Topic Chair: Black 09:00 09:30 Animal Models of Bladder Cancer Cory Abate-Shen 09:30 09:40 Discussion Potpourri Topic Chair: Goebell 09:40 09:47 Phase I trial of rbcg Rentsch 09:47 09:54 Treatment of oligometastatic bladder Navai 09:54 10:01 Collaborative Effort in Bladder Sarcoma Luz Research 10:01 10:08 IBCN recommendations for MIBC followup Kamat
4 10:08 10:20 Discussion 10:20 10:27 Uncovering the TWEAK/Fn14 cytokinereceptor Sanchez-Carbayo axis in bladder 10:27 10:34 CD4+ expansion after BCG Bivalacqua 10:34 10:41 Myeloid derived suppressor cells Grivas (**Travel Award**) 10:41 10:50 Discussion Break 10:50 11:05 Molecular Topic Chair: Black Subtyping 11:05 11:17 Molecular subtyping of advanced bladder Sjödahl 11:17 11:29 TCGA Update Lerner 11:29 11:41 Molecular subtypes and response to McConkey immune therapy in NMIBC 11:41 11:53 Response to neoadjuvant chemotherapy Seiler in MIBC is dependent on molecular subtypes 11:53 12:10 Discussion 12:10 12:22 Subtype specific bladder mouse models Kim 12:22 12:34 Validation of 12 gene progression score Dyrskjot in NMIBC 12:34 12:46 Molecular subtypes in micropapillary Guo urothelial carcinoma 12:46 12:58 Forerunner genes - basa to luminal Czerniak differentiation checkpoint 12:58 13:15 Discussion Lunch Break 13:15 14:00 Urine Topic Chair: Zwarthoff Biomarkers 14:00 14:07 Urinary gene expression test Mengual 14:07 14:14 Epigenetic markers in tissue and urine Smit 14:14 14:21 Hypermethylation of 4 gene panel for van Kessel prediction of progression of NMIBC 14:21 14:28 Urine proteomic biomarker panel Vlahou 14:28 14:35 Survivin and UBC Rapide for Gleichenhagen
5 detection of bladder 14:35 14:50 Discussion Chromatin Topic Remodeling 14:50 15:10 Functional analysis of chromatin remodeling genes 15:10 15:17 Chromatin remodeling gene mutations and T-cell infiltration 15:17 15:32 Genome-wide RNAi screen identifies novel ploidy-control genes that associate with recurrent mutations in human Discussion Chair: Nawroth Schulz Sfakianos Günes Wrap-Up & Closing Remarks 16:00 Kamat and Goebell
Program 12 th Meeting of the IBCN September th, 2014, Vancouver, Canada
THURSDAY, SEPTEMBER 25 TH, 2014 19.00 Welcome Dinner Cactus Club, Yaletown (357 Davie St) FRIDAY, SEPTEMBER 26 TH, 2014 Introduction Topic Speaker 07:30 08:00 Registration/Light breakfast 08:00 08:15 Welcome
SCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:
ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.
High risk non-muscle invasive bladder cancer: From guidelines to future approaches Chairs: A. Lopez Beltran, Lisbon (PT)
Friday, 8 June 2018 EAU Update on Bladder Cancer (BCa18) Challenging your knowledge of the EAU Guidelines 8-9 June 2018, Munich, Germany Steering committee: F. Montorsi, H. Van Poppel and M. Wirth Scientific
Novel therapeutic strategies for NMIBC. Peter Black Vancouver Prostate Centre University of British Columbia
Novel therapeutic strategies for NMIBC Peter Black Vancouver Prostate Centre University of British Columbia Financial and Other Disclosures I have the following financial interests or relationships to
Options for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
January 10-12, Westin Harbour Castle Toronto, ON #CUOS19. cuos2019.org
January 10-12, 2019 Westin Harbour Castle Toronto, ON #CUOS19 cuos2019.org Scientific Program Committee Co-Chairs: Neil Fleshner, CUOG Aly-Khan Lalani, GUMOC Himu Lukka, GUROC Andy Evans, CNUP Tony Finelli,
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
2016 CRUK Lung Cancer Centre of Excellence Student/Postdoc Winter Workshop Programme
2016 CRUK Lung Cancer Centre of Excellence Student/Postdoc Winter Workshop Programme Thursday 1 st December 2016 09.15am 10.00am Registration and Refreshments 10.15am 10.30am Welcome 10.30am 11.15am Opening
Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease
Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Biology of urothelial tumorigenesis: insights from genetically
Neoplasie uroteliali 2017 Highlights. Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Neoplasie uroteliali 2017 Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy Disclosures Consulting or Advisory Role: Company: Roche, Bayer, Merck & Co. Inc., Astra
Updates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
Urothelial Carcinoma Highlights
Urothelial Carcinoma Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano European Association of Urology Research Foundation Disclosures Consulting or Advisory Role: Company:
Disclosure. Astellas. Research funding. Advisory board (to institute) Roche/Genentech Astra Zeneca/Medimmune Astellas
Disclosure Activity Company Research funding Advisory board (to institute) Astellas Roche/Genentech Astra Zeneca/Medimmune Astellas Immunotherapy for urothelial cell carcinoma A NEW HOPE Michiel van der
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
Oral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
Next-generation sequencing in non-muscle-invasive bladder cancer a step towards personalized medicine for a superficial bladder tumor
Editorial Next-generation sequencing in non-muscle-invasive bladder cancer a step towards personalized medicine for a superficial bladder tumor Andrew Butterfield, Sumati Gupta Huntsman Cancer Institute,
:00-13:00 Industry Satellite Symposium 1 Room A. 13:00-13:30 Welcome reception Hall 1. 13:30-13:45 Opening and welcome Room B
04-10-2019 12:00-13:00 Industry Satellite Symposium 1 Room A 13:00-13:30 Welcome reception Hall 1 13:30-13:45 Opening and welcome Room B 13:45-14:15 HHH Award lecture Room B 13:45-14:15 HHH Award lecture
2017 Program Schedule August 3-5, 2017 Charlotte, NC Collaborating to Move Research Forward
2017 Program Schedule August 3-5, 2017 Charlotte, NC Collaborating to Move Research Forward Thursday, August 3 10:00 1:00 Patient Advocacy Session (for patient advocates only) 2:00 4:00 Registration 1:30
A Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting
International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
Non Muscle Invasive Bladder Cancer (NMIBC) Experts Discuss Treatment Options. Part II: The Future Treatment of NMIBC
Non Muscle Invasive Bladder Cancer (NMIBC) Experts Discuss Treatment Options Wednesday, June 14, 2017 Part II: The Future Treatment of NMIBC Presented by Dr. Arlene Siefer-Radtke is an Associate Professor
2016 SUMMER RESEARCH CONFERENCE AUA/SBUR 2016 SUMMER RESEARCH CONFERENCE. Targeting Epigenetics and Genome Regulation to Improve Urologic Health
2016 SUMMER RESEARCH CONFERENCE AUA/SBUR 2016 SUMMER RESEARCH CONFERENCE Targeting Epigenetics and Genome Regulation to Improve Urologic Health AUA Headquarters Linthicum, MD JULY 16-17, 2016 Understanding
January 10-12, Westin Harbour Castle Toronto, ON #CUOS19. cuos2019.org
January 10-12, 2019 Westin Harbour Castle Toronto, ON #CUOS19 cuos2019.org Scientific Program Committee Co-Chairs: Neil Fleshner, CUOG Aly-Khan Lalani, GUMOC Himu Lukka, GUROC Andy Evans, CNUP Tony Finelli,
Biobanking of Breast Cancer: Ultimately leading to prevention of brain metastases
Biobanking of Breast Cancer: Ultimately leading to prevention of brain metastases A.Hoeben, MD PhD Medical Oncologist Content. Introduction: -> need to optimize current treatment options for brain metastasized
Juravinski Cancer Centre Uro-Oncology Forum April 13-14, 2018 Pillar & Post Inn Niagara-on-the-Lake, ON #JCC18.
Juravinski Cancer Centre Uro-Oncology Forum 2018 April 13-14, 2018 Pillar & Post Inn Niagara-on-the-Lake, ON #JCC18 Final Program STEERING COMMITTEE, Chair Sebastien Hotte Himu Lukka Bobby Shayegan The
Daniel Lieber, Ph.D. Senior Scientist, Computational Biology Foundation Medicine, Cambridge, MA. AACR 2017: Clinical Biomarkers April 3, 2017
Validation & clinical feasibility of a comprehensive genomic profiling assay to identify likely immunotherapy responders through tumor mutational burden (TMB) Daniel Lieber, Ph.D. Senior Scientist, Computational
Colorectal Cancer in 2017: From Biology to the Clinics. Rodrigo Dienstmann
Colorectal Cancer in 2017: From Biology to the Clinics Rodrigo Dienstmann MOLECULAR CLASSIFICATION Tumor cell Immune cell Tumor microenvironment Stromal cell MOLECULAR CLASSIFICATION Biomarker Tumor cell
BCG Unresponsive Disease A Roadmap for Drug Development and Integra;on of Novel Therapies
BCG Unresponsive Disease A Roadmap for Drug Development and Integra;on of Novel Therapies Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College of
Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure. Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS
Optimising the management of non-muscle invasive bladder cancer from diagnosis to cure Dr Richard Savdie Uro-Oncology Fellow BSc MBBS FRACS Objectives 1. Explore best practice diagnostic techniques 2.
5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition
5th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition SIXTH DRAFT OF THE PROGRAM AUGUST 28, 2014 Wednesday, October 5, 2016 08:00-16:30 Post Graduate course (To be developed by the
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Radical Cystectomy
Decipher Bladder Predicts Which Patients May Benefit from Neoadjuvant Chemotherapy Prior to Cystectomy Contact the GenomeDx Customer Support Team 1.888.792.1601 (toll-free) customersupport@genomedx.com
April 26 th April 29 th, 2017 Kibbutz Hagoshrim, Israel WEDNESDAY, APRIL 26, rd International Congress on Molecular Targeting Therapy
3 rd International Congress on Molecular Targeting Therapy April 26 th April 29 th, 2017 Kibbutz Hagoshrim, Israel WEDNESDAY, APRIL 26, 2017 Update: Mar. 12 14:00-21:00 Registration & Check-In 16:00-17:00
Immunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma
Kamat et al. Journal for ImmunoTherapy of Cancer (2017) 5:68 DOI 10.1186/s40425-017-0271-0 POSITION ARTICLE AND GUIDELINES Society for Immunotherapy of Cancer consensus statement on immunotherapy for the
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
Challenging Genitourinary Tumors: What s New in 2017
Challenging Genitourinary Tumors: What s New in 2017 David J. Vaughn, MD Genitourinary Medical Oncology Professor Please note that some of the studies reported in this presentation were presented as an
2019 Program Schedule August 8-10, 2019 Washington, DC Collaborating to Move Research Forward
Thursday, August 8 9:00 11:00 Patient Advocacy Session (for patient advocates only) 2019 Program Schedule August 8-10, 2019 Washington, DC Collaborating to Move Research Forward 11:00 4:00 Save-the-Date:
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
BCG Unresponsive NMIBC: What s Available?
BCG Unresponsive NMIBC: What s Available? Michael S. Cookson, MD, MMHC, FACS Professor and Chair Department of Urology University of Oklahoma TwiLer @uromc Professional Practice Gap Gap 1: There is incomplete
Melanoma Summit. DRAFT programme. New Zealand November 2018 Cordis Hotel, Auckland. As at 1 September Subject to change.
Melanoma Summit New Zealand 2018 2 3 November 2018 Cordis Hotel, Auckland DRAFT programme As at 1 September 2018 Subject to change. Friday 2 November 2018 TIME TOPIC PRESENTER 0830 Mihi whakatau 0845 Formal
Challenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Challenges in systemic treatment for metastatic bladder cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University OS PCG 15.8 vs GC 12.7 NS Cisplatin ineligible Second-line chemotherapy
PRACTICAL Urology. USC Institute of Urology 4 th Annual Conference: Guest Faculty. Thursday January 31, January 31, February 1 2, 2019
USC Institute of Urology 4 th Annual Conference: PRACTICAL Urology January 31, February 1 2, 2019 Guest Faculty Jeffrey Cadeddu, MD University of Texas Southwestern University of Michigan University of
SCIENTIFIC TIMETABLE SIOP 2015
SCIENTIFIC TIMETABLE SIOP 2015 September, 2015 WEDNESDAY, 7 TH OCTOBER 2015 / DAY 2 1.43 09:30 SIOP Committee 12:00 SIOP Essential Drugs Working 13:00 SIOP Work (Open) 14:00 Nurse Researchers 16:00 17:00
Reviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
DFG. DFG Hinterzartener Kreis für Krebsforschung. From Molecular Mechanisms to Targeted Cancer Therapy
DFG Hinterzartener Kreis für Krebsforschung From Molecular Mechanisms to Targeted Cancer Therapy April 26-29, 2012 Villa La Collina Cadenabbia (Co), Italy Program Committee Cathrin Brisken, Lausanne (Chair)
Emerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
NEW RESEARCH AND CLINICAL FRONTIERS IN BLADDER AND KIDNEY CANCER
NEW RESEARCH AND CLINICAL FRONTIERS IN BLADDER CANCER LEVERAGING EXISTING STRENGTHS The exceptional quality of the research enterprise at the Vancouver Prostate Centre (VPC) is recognized around the world
Cancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO Montse Domènech Althaia, Xarxa Assistencial i Universitària Manresa Urothelial Cancer Therapeutics FDA approved drugs for bladder
Preliminary Programme
Preliminary Programme THURSDAY 26 April 2018 08.15-09.00 Registration desk 09.00-09.10 Welcome Address: Update in Breast Imaging B. Claikens (Ostend, BE) SESSION 1 Chairman : R. Pijnappel (Nijmegen, NED)
Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
Urinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
Hall 406. Title: Opening & Keynote. Hall 405. Title: Treatment of node positive bladder. Hall 404
23-11-2018 10:00-11:30 Type: Opening session Title: Opening & Keynote Hall 406 11:45-12:30 Type: Challenge Your Expert session Title: Treatment of node positive bladder 11:45-11:55 Treatment of node positive
Roche Investor Relations ASCO Planner 2016
Roche Investor Relations ASCO Planner 2016 Friday, June 3 Session Title: Pediatric Oncology I Date: Fri, June 3 Location: S504 Time: 3:00 PM - 6:00 PM Speaker Name: Veronique Minard-Colin 5:12 PM - 5:24
Integrating Immunotherapy into Urologic Oncology: The New Urothelial Cancer Paradigm
Immunotherapy in Urothelial Cancer: Where are We Now & Where are We Going? Arjun Balar, MD Director of Genitourinary Medical Oncology Program NYU Langone Medical Center New York, NY Bladder Cancer Therapeutic
Urothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium
Bladder Cancer 3 (2017) 211 223 DOI 10.3233/BLC-170111 IOS Press Meeting Report 211 Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium Thomas W. Flaig a,, Ashish M. Kamat
EORTC LUNG CANCER GROUP GROUP MEETING
Sunday 7 th October 2018 Time slot Topic / Title of presentation Chair 9.00 11.00 Board meeting 11.00 11.30 Arrivals & Welcome coffee 11.30 11.50 Welcome & Introduction New Board,, Membership status, Calendar
Roche Pharma Day 2015
Roche Pharma Day 2015 Molecular Information Garret Hampton VP, Oncology Biomarker Development Pharmaceuticals Division Personalized healthcare A cornerstone of the Genentech / Roche strategy Diagnostics
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline Jeffrey M. Holzbeierlein, MD, FACS John W Weigel Professor & Chair Director of Urologic Oncology University of Kansas
FALL MEETING. Sitges, 7th and 8th October, Venue. ME Sitges Terramar Hotel Passeig Marítim, Sitges, Barcelona
FALL MEETING Sitges, 7th and 8th October, 2018 Venue ME Sitges Terramar Hotel Passeig Marítim, 80 08870 Sitges, Barcelona Sunday 7 th October 2018 Time slot Topic / Title of presentation Chair 9.00 11.00
Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
ICLIO National Conference
ICLIO National Conference Immuno-oncology In The Clinic Today Lee Schwartzberg, MD, FACP Executive Director, West Cancer Center Chief, Division of Hematology/Oncology University of Tennessee Health Science
Core Curriculum for the Cardiovascular Clinician
September 14 17, 2016 Heart House Washington, DC AGENDA Wednesday, September 14 PHARMACOLOGY WORKSHOP 5:30 p.m. Registration and Light Refreshments 6:00 p.m. Welcome and Introductions 6:15 p.m. CVD Guideline-driven
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
788310TAM0010.1177/1758835918788310Therapeutic Advances in Medical OncologyP Ghatalia, M Zibelman research-article20182018 Therapeutic Advances in Medical Oncology Review Approved checkpoint inhibitors
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
NECA Future Leaders Conference April 18-20, 2012 Irving, Texas Evaluation Results
NECA Future Leaders Conference April 18-20, 2012 Irving, Texas Evaluation Results Please let us know how useful you found the following sessions at the NECA Future Leaders Conference and share any comments
Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
Review Article Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer? Felix Wezel 1 *, Stefan Vallo 2 *, Florian Roghmann 3 ; On behalf
Media Release. Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Media Release Basel, 3 May 2016 Roche highlights personalised medicines and cancer immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting 19 Roche medicines are included in
Media Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
Chemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
ORIEN NOVA TEAM SCIENCE AWARD
ORIEN NOVA TEAM SCIENCE AWARD CALL FOR LETTERS OF INTENT BACKGROUND: The Oncology Research Information Exchange Network (ORIEN) is a unique alliance to integrate data sharing and collaborative learning
Licia Rivoltini, MD Unit of Immunotherapy of Human Tumors
Licia Rivoltini, MD Unit of Immunotherapy of Human Tumors The complex network of anti-tumor immunity Innate immunity First line defense Tumor cell Adaptive immunity Specificity & memory Kidd et al., Nature
R&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
PROVISIONAL SCIENTIFIC PROGRAMME AND TIMETABLE
PROVISIONAL SCIENTIFIC PROGRAMME AND TIMETABLE Thursday 17 th October, 2013 09.00- : Executive meetings (only for the Executive and the International Advisory Boards of EURIPA and the Executive of EGPRN),
2019 Mayo Clinic Urology Review Program Schedule
2019 Mayo Clinic Urology Review Program Schedule Monday, January 21, 2019 6:00 a.m. Registration & Breakfast with Exhibitors 6:50 Welcome Announcements PROSTATE CANCER 7:00 Management of Castrate Resistant
Immunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Media Release Basel, 10 May 2017 Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary
8th Annual Bladder Cancer Think Tank
8th Annual Bladder Cancer Think Tank Collaborating to Move Research Forward On August 8-10, 2013, more than 120 leading clinicians, researchers, patient advocates, and industry representatives convened
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors Daniel P Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
Tuesday 25th October
14.00-1700 Tuesday 25th October Registration Open 17.00-19.30 Welcome Reception Wednesday 26th October 1 In Situ Disease and Screening Current Perspectives on the Classification and Significance of In
Special Situation: Brain metastases
ESMO Advanced Course on Unsolved Questions in Immuno-Oncology February 16-17 2018, Amsterdam, Netherlands Special Situation: Brain metastases Matthias Preusser, MD Associate Professor of Medicine Department
Patient Selection and Sequencing of Therapies in the New Melanoma Landscape
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
Prostate & Urologic Cancers Symposium
REGISTER ONLINE: OUHSC.CLOUD-CME.COM FOURTH ANNUAL OKLAHOMA Prostate & Urologic Cancers Symposium FRIDAY SEPT. 14 2018 GUEST SPEAKER: Christopher J. Kane, MD University of California - San Diego Earn 5.75
Clinical management of BRCA mutation carriers and those at high risk of breast cancer. Provisional Program
Clinical management of BRCA mutation carriers and those at high risk of breast cancer Provisional Program Thursday, November 22 14.00 18.00 Live operating session - Bilateral risk reducing mastectomy case
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
SINGAPORE. 12 th PVRI Annual World Congress. on Pulmonary Vascular Disease WELCOME TO. Date // January 2018
Date // 21-25 January 2018 12 th PVRI Annual World Congress on Disease Hotel // Mandarin Orchard Hotel. Singapore WELCOME TO SINGAPORE Pre-Congress MEETINGS Sunday 21 January 2018 PVRI Board of Directors
BREAST CANCER 2013: Seeing the Future
Presented by BREAST CANCER 2013: Seeing the Future Friday May 24, 2013 8:00 AM - 3:00 PM Doubletree at Hilton Cleveland East 3663 Park East Drive Beachwood, OH 44122 Sponsored by COURSE OVERVIEW This course
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology
SOIL HEALTH HUMAN HEALTH CONFERENCE
SPONSOR BRIEF CONFERENCE on CONNECTIONS BETWEEN SOIL HEALTH and HUMAN HEALTH Tuesday, October 16 th Wednesday, October 17 th, 2018 Doubletree by Hilton, Silver Spring, MD Planned for 150 Attendees (Half
October 12 13, 2018 New York Marriott Marquis New York, New York. The premier conference for annual updates in lung cancer. 23rd Annual Conference
The premier conference for annual updates in lung cancer 23rd Annual Conference October 12 13, 2018 New York Marriott Marquis New York, New York Reserve your place today: thoraciccancermeeting.com Perspectives
24th Annual Prostate Cancer Foundation Scientific Retreat
24th Annual Prostate Cancer Foundation Scientific Retreat October 5-7, 2017 Omni Shoreham Hotel Washington D.C. 1 AGENDA Thursday, October 5, 2017 GENERAL SESSIONS Location: Regency Ballroom 8:00 AM Registration
Tecentriq. Tecentriq (atezolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.80 Subject: Tecentriq Page: 1 of 5 Last Review Date: September 15, 2017 Tecentriq Description Tecentriq
Cancer Diagnosis and Treatment August 02-03, 2018 Oslo, Norway
Tentative Program International Conferences on Cancer Diagnosis and Treatment August 02-03, 2018 Oslo, Norway ***For available SPEAKER SLOTS*** Conference Series llc LTD 47 Churchfield Road, London, W36AY,
Melanoma Summit. DRAFT programme. New Zealand November 2018 Cordis Hotel, Auckland. As at 27 June Subject to change.
Melanoma Summit New Zealand 2018 2 3 November 2018 Cordis Hotel, Auckland DRAFT programme As at 27 June 2018 Subject to change. Friday 2 November 2018 TIME TOPIC PRESENTER 0830 Mihi whakatau 0845 Formal
Junior Achievers of the Blind
Junior Achievers of the Blind Conference Agenda Draft 6/13/2017 Thursday, August 3 rd 4:00 PM 5:30 PM Check In 5:30 PM 6:30 PM Tour of Hotel 7:00 PM 8:30 PM Dinner/Social Burger, Taco, or Pasta Bar 8:30
3 rd Berlin Cancer Retreat - Agenda
3 rd Berlin Cancer Retreat - Agenda Wednesday, 5 October 2016 8:30 9:00 Registration 9:00 9:10 Welcome and Introduction Program Exploitation of Oncogenic Mechanisms Ulrike Stein 9:10 9:25 Targeting Myc